曲妥珠单抗联合化疗在接受改良根治术并行术后化疗初治乳腺癌患者中的应用  

Application of Trastuzumab combined with chemotherapy in patients with breast cancer who underwent modified radical mastectomy and postoperative chemotherapy

作　　者：龚玉爱 舒诚荣[1] 韩琦[1] GONG Yu-ai;SHU Cheng-rong;HAN Qi(Department of Oncology,Xianning Central Hospital(the First Affiliated Hospital of Hubei University of Science and Technology),Hubei Province,Xianning437100,China)

机构地区：[1]湖北省咸宁市中心医院湖北科技学院附属第一医院肿瘤科,湖北咸宁437100

出　　处：《中国当代医药》2020年第22期83-86,共4页China Modern Medicine

摘　　要：目的探讨曲妥珠单抗联合化疗在接受改良根治术并行术后化疗初治乳腺癌患者的作用。方法选取2015年1月~2017年1月我院收治的81例接受改良根治术并行术后化疗的初治乳腺癌患者作为研究对象,按照随机数字表法分为对照组(40例)与研究组(41例)。对照组采用多西他赛^+卡铂方法,研究组采用曲妥珠单抗联合化疗方法。比较两组的肿瘤负荷、免疫功能。结果研究组血清肿瘤标志物癌胚抗原(CEA)、糖类抗原(CA)199、CA153、CA125水平均低于对照组,差异有统计学意义(P<0.05);研究组血清肿瘤活性分子血管内皮生长因子(VEGF)、结合素-4(nectin-4)、胸苷激酶-1(TK-1)、血小板第4因子(PF-4)、肿瘤特异生长因子(TSGF)水平均低于对照组,差异有统计学意义(P<0.05);研究组血清CD3^+、CD4^+淋巴细胞比例、CD4^+/CD8^+比值均高于对照组,CD8^+淋巴细胞比例低于对照组,差异有统计学意义(P<0.05)。结论乳腺癌改良根治术后采用曲妥珠单抗联合化疗能够降低乳腺癌患者肿瘤负荷,改善机体免疫应答反应,具有临床推广应用价值。Objective To explore the application of Trastuzumab combined with chemotherapy in patients with breast cancer who underwent modified radical mastectomy and postoperative chemotherapy.Methods A total of 81 patients with newly treated breast cancer who underwent modified radical mastectomy and postoperative chemotherapy in our hospital from January 2015 to January 2017 were selected as research subjects.They were divided into a control group(n=40)and a study group(n=41)according to random number table method.The control group was treated with Docetaxel+Carboplatin method,and the study group was treated with combination of Trastuzumab and chemotherapy.The tumor load and immunity function of the two groups were compared.Results The levels of serum tumor markers including carcinoembryonic antigen(CEA),carbohydrate antigen(CA)199,CA153,and CA125 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of serum tumor active molecules like vascular endothelial growth factor(VEGF),nectin-4,thymidine kinase-1(TK-1),platelet factor 4(PF-4),and tumor specific growth factor(TSGF)in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).The ratio of serum CD3+,CD4+lymphocyte,and CD4+/CD8+in the study group were higher than those in the control group,and the ratio of CD8+lymphocyte was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion The use of Trastuzumab combined with chemotherapy after improved radical mastectomy for breast cancer can reduce the tumor of breast cancer patients and improve their immune response,which has clinical application value.

关 键 词：乳腺癌 曲妥珠单抗 肿瘤负荷 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]